Quoin Pharmaceuticals
QNRX
2 hedge funds and large institutions have $7.22K invested in Quoin Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.24% less ownership
Funds ownership: 0.41% → 0.18% (-0.24%)
70% less capital invested
Capital invested by funds: $24K → $7.22K (-$16.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.78K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.7K |
QNRX Hedge Fund Activity: Q3 2023 in Review
2 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q3 2023, worth a combined $7.22K — down 70% from $24K a quarter earlier.
Fund positioning in QNRX was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $4.78K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $19.7K sold.
- 2 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $7.22K of Quoin Pharmaceuticals stock for Q3 2023, down 70% quarter-over-quarter.
- 1 fund opened new Quoin Pharmaceuticals positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest Quoin Pharmaceuticals buyer in Q3 2023 was UBS Group, an estimated $4.78K added.
- The largest Quoin Pharmaceuticals seller in Q3 2023 was Susquehanna International Group, an estimated $19.7K sold.
Based on aggregated 13F filings for Q3 2023.